Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Gross Profit: 2021-2025

Historic Gross Profit for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$43,292.

  • SAB Biotherapeutics' Gross Profit rose 44.52% to -$43,292 in Q3 2025 from the same period last year, while for Sep 2025 it was -$62,504, marking a year-over-year decrease of 104.36%. This contributed to the annual value of $1.3 million for FY2024, which is 40.94% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Gross Profit of -$43,292 as of Q3 2025, which was up 32.72% from -$64,345 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Gross Profit ranged from a high of $18.2 million in Q2 2021 and a low of -$78,036 during Q3 2024.
  • Over the past 3 years, SAB Biotherapeutics' median Gross Profit value was $114,698 (recorded in 2024), while the average stood at $300,560.
  • Per our database at Business Quant, SAB Biotherapeutics' Gross Profit soared by 207.70% in 2024 and then tumbled by 124.45% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Gross Profit (Quarterly) stood at $11.1 million in 2021, then tumbled by 80.46% to $2.2 million in 2022, then crashed by 85.88% to $305,011 in 2023, then slumped by 62.40% to $114,698 in 2024, then skyrocketed by 44.52% to -$43,292 in 2025.
  • Its last three reported values are -$43,292 in Q3 2025, -$64,345 for Q2 2025, and -$69,565 during Q1 2025.